1-3 of 3
Nazan Ozsan
Close
Sort by
Journal Articles

Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP

Clinical Trials & Observations
Mamta Gupta, Matthew J. Maurer, Linda E. Wellik, Mark E. Law, Jing Jing Han, Nazan Ozsan, Ivana N. Micallef, Ahmet Dogan, Thomas E. Witzig
Journal: Blood
Blood (2012) 120 (22): 4400–4406.
https://doi.org/10.1182/blood-2012-05-428466
Published: 2012
Includes: Supplemental data
Journal Articles

Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas

George Vasmatzis, Sarah H. Johnson, Ryan A. Knudson, Rhett P. Ketterling, Esteban Braggio, Rafael Fonseca, David S. Viswanatha, Mark E. Law, N. Sertac Kip, Nazan Özsan, Stefan K. Grebe, Lori A. Frederick, Bruce W. Eckloff, E. Aubrey Thompson, Marshall E. Kadin, Dragana Milosevic, Julie C. Porcher, Yan W. Asmann, David I. Smith, Irina V. Kovtun, Stephen M. Ansell, Ahmet Dogan, Andrew L. Feldman
Journal: Blood
Blood (2012) 120 (11): 2280–2289.
https://doi.org/10.1182/blood-2012-03-419937
Published: 2012
Includes: Supplemental data
Journal Articles

Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing

Brief Report
Andrew L. Feldman, Ahmet Dogan, David I. Smith, Mark E. Law, Stephen M. Ansell, Sarah H. Johnson, Julie C. Porcher, Nazan Özsan, Eric D. Wieben, Bruce W. Eckloff, George Vasmatzis
Journal: Blood
Blood (2011) 117 (3): 915–919.
https://doi.org/10.1182/blood-2010-08-303305
Published: 2011
Includes: Supplemental data